Rheumatology

Nonsteroidal anti-inflammatory drugs put the fetus at risk for rare but serious kidney complications.

A Janus kinase inhibitor was approved for the treatment of active polyarticular course juvenile idiopathic arthritis among patients aged 2 years or older.

The US Food and Drug Administration has approved tofacitinib for the treatment of active polyarticular course juvenile idiopathic arthritis among pediatric patients aged 2 years or older.

The drug was given priority review status by the FDA and was approved to treat adults with the rare, severe autoimmune disease.

After the clinical trial showed positive results, the first treatment option for children with systemic lupus erythematosus has been approved.

After the clinical trial showed positive results, the first treatment option for adults with inflammatory arthritis in the spine has been approved.

The US Food and Drug Administration recently approved a biosimilar to Humira for the treatment of multiple inflammatory diseases in adult patients.